Upstate joins NHIA in COVID treatment program
By HME News Staff
Updated 9:10 AM CDT, Wed June 2, 2021
SYRACUSE, N.Y. – Upstate HomeCare has partnered with the National Home Infusion Therapy Association to offer monoclonal antibody therapies to patients with mild and moderate COVID-19. The NHIA COVID-19 Home Infusion Therapy (C-HIT) Program hosts an online listing of home infusion providers that have agreed to provide these therapies to eligible individuals in their communities. “Upstate HomeCare is proud to be part of the U.S. health care response to the pandemic in our community,” said Greg LoPresti, CEO. “Decreasing hospital admissions is our first priority, and our pharmacists and nurses are ready to help those most in need. We look forward to working with prescribers to reach at-risk patients who can benefit from these very effective therapies.” NHIA will collect utilization and clinical outcome data from home infusion providers for the purposes of sharing information about the safety and efficacy of COVID-19 mABs. Monoclonal antibodies have been shown to be highly effective in preventing severe disease and death in high-risk individuals if the one-time infusion is administered within 10 days of symptom onset.
Comments